Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance
Background Despite the remarkable success of immunotherapy in treating melanoma, understanding of the underlying mechanisms of resistance remains limited. Emerging evidence suggests that upregulation of tumor-specific major histocompatibility complex-II (tsMHC-II) serves as a predictive marker for t...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/11/11/e007736.full |
| _version_ | 1827287094121201664 |
|---|---|
| author | Violeta Sánchez Yaomin Xu Douglas B Johnson Emily Hodges Margaret L Axelrod Justin M Balko Xiaopeng Sun Brandie C Taylor Catherine C Fahey Jamaal L James Lindsey N Guerin Paula I Gonzalez-Ericsson Melinda E Sanders |
| author_facet | Violeta Sánchez Yaomin Xu Douglas B Johnson Emily Hodges Margaret L Axelrod Justin M Balko Xiaopeng Sun Brandie C Taylor Catherine C Fahey Jamaal L James Lindsey N Guerin Paula I Gonzalez-Ericsson Melinda E Sanders |
| author_sort | Violeta Sánchez |
| collection | DOAJ |
| description | Background Despite the remarkable success of immunotherapy in treating melanoma, understanding of the underlying mechanisms of resistance remains limited. Emerging evidence suggests that upregulation of tumor-specific major histocompatibility complex-II (tsMHC-II) serves as a predictive marker for the response to anti-programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) therapy in various cancer types. The genetic and epigenetic pathways modulating tsMHC-II expression remain incompletely characterized. Here, we provide evidence that polycomb repressive complex 2 (PRC2)/EZH2 signaling and resulting H3K27 hypermethylation suppresses tsMHC-II.Methods RNA sequencing data from tumor biopsies from patients with cutaneous melanoma treated with or without anti-PD-1, targeted inhibition assays, and assays for transposase-accessible chromatin with sequencing were used to observe the relationship between EZH2 inhibition and interferon (IFN)-γ inducibility within the MHC-II pathway.Results We find that increased EZH2 pathway messenger RNA (mRNA) expression correlates with reduced mRNA expression of both presentation and T-cell genes. Notably, targeted inhibition assays revealed that inhibition of EZH2 influences the expression dynamics and inducibility of the MHC-II pathway following IFN-γ stimulation. Additionally, our analysis of patients with metastatic melanoma revealed a significant inverse association between PRC2-related gene expression and response to anti-PD-1 therapy.Conclusions Collectively, our findings demonstrate that EZH2 inhibition leads to enhanced MHC-II expression potentially resulting from improved chromatin accessibility at CIITA, the master regulator of MHC-II. These insights shed light on the molecular mechanisms involved in tsMHC-II suppression and highlight the potential of targeting EZH2 as a therapeutic strategy to improve immunotherapy efficacy. |
| first_indexed | 2024-03-09T08:33:00Z |
| format | Article |
| id | doaj.art-9daebf72a8f642c3941201c11f10699f |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-04-24T10:51:14Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-9daebf72a8f642c3941201c11f10699f2024-04-12T12:20:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-01111110.1136/jitc-2023-007736Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistanceVioleta Sánchez0Yaomin Xu1Douglas B Johnson2Emily Hodges3Margaret L Axelrod4Justin M Balko5Xiaopeng Sun6Brandie C Taylor7Catherine C Fahey8Jamaal L James9Lindsey N Guerin10Paula I Gonzalez-Ericsson11Melinda E Sanders12Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USADepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USADepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USADepartment of Biochemistry, Vanderbilt University, Nashville, Tennessee, USADepartment of Medicine, Washington University in St Louis, St Louis, Missouri, USABreast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee, USADepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USADepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USAVanderbilt University Medical Center, Nashville, TN, USADepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USADepartment of Biochemistry, Vanderbilt University, Nashville, Tennessee, USADepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USABreast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee, USABackground Despite the remarkable success of immunotherapy in treating melanoma, understanding of the underlying mechanisms of resistance remains limited. Emerging evidence suggests that upregulation of tumor-specific major histocompatibility complex-II (tsMHC-II) serves as a predictive marker for the response to anti-programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) therapy in various cancer types. The genetic and epigenetic pathways modulating tsMHC-II expression remain incompletely characterized. Here, we provide evidence that polycomb repressive complex 2 (PRC2)/EZH2 signaling and resulting H3K27 hypermethylation suppresses tsMHC-II.Methods RNA sequencing data from tumor biopsies from patients with cutaneous melanoma treated with or without anti-PD-1, targeted inhibition assays, and assays for transposase-accessible chromatin with sequencing were used to observe the relationship between EZH2 inhibition and interferon (IFN)-γ inducibility within the MHC-II pathway.Results We find that increased EZH2 pathway messenger RNA (mRNA) expression correlates with reduced mRNA expression of both presentation and T-cell genes. Notably, targeted inhibition assays revealed that inhibition of EZH2 influences the expression dynamics and inducibility of the MHC-II pathway following IFN-γ stimulation. Additionally, our analysis of patients with metastatic melanoma revealed a significant inverse association between PRC2-related gene expression and response to anti-PD-1 therapy.Conclusions Collectively, our findings demonstrate that EZH2 inhibition leads to enhanced MHC-II expression potentially resulting from improved chromatin accessibility at CIITA, the master regulator of MHC-II. These insights shed light on the molecular mechanisms involved in tsMHC-II suppression and highlight the potential of targeting EZH2 as a therapeutic strategy to improve immunotherapy efficacy.https://jitc.bmj.com/content/11/11/e007736.full |
| spellingShingle | Violeta Sánchez Yaomin Xu Douglas B Johnson Emily Hodges Margaret L Axelrod Justin M Balko Xiaopeng Sun Brandie C Taylor Catherine C Fahey Jamaal L James Lindsey N Guerin Paula I Gonzalez-Ericsson Melinda E Sanders Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance Journal for ImmunoTherapy of Cancer |
| title | Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance |
| title_full | Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance |
| title_fullStr | Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance |
| title_full_unstemmed | Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance |
| title_short | Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance |
| title_sort | polycomb repressor complex 2 suppresses interferon responsive mhc ii expression in melanoma cells and is associated with anti pd 1 resistance |
| url | https://jitc.bmj.com/content/11/11/e007736.full |
| work_keys_str_mv | AT violetasanchez polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT yaominxu polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT douglasbjohnson polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT emilyhodges polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT margaretlaxelrod polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT justinmbalko polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT xiaopengsun polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT brandiectaylor polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT catherinecfahey polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT jamaalljames polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT lindseynguerin polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT paulaigonzalezericsson polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance AT melindaesanders polycombrepressorcomplex2suppressesinterferonresponsivemhciiexpressioninmelanomacellsandisassociatedwithantipd1resistance |